



Contact:

Karen A. Donato, Ph.D.
Executive Vice President, Sales and Marketing
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte Demonstrates How to Develop and Optimize Scalable Cell Based Assays at the MipTec 2010 Conference in Basel, Stand G16

*MaxCyte® STX™ Scalable Transfection System for Cell Based Assays:
Workshop and Other Events at the MipTec 2010 Conference*

Gaithersburg, MD, September 22, 2010 –MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, will sponsor and host several events at the MipTec 2010 Conference this week at the Congress Center in Basel, Switzerland.

Dr. James Brady, Director of Technical Applications at MaxCyte, will conduct an Industry Symposium on Thursday, September 23, at 12:45 PM in Lecture Hall F to demonstrate how the MaxCyte® STX™ Scalable Transfection System can be used to quickly and efficiently develop and optimize cell-based assays that scale seamlessly and power up from the bench to the high throughput screening line. In addition to demonstrating the simple operation of the MaxCyte STX to transfect any cell with any molecule at any scale quickly and reproducibly, Dr. Brady will present case studies generated by customers using the MaxCyte STX in their drug discovery and development programs.

MaxCyte is also participating as a Sponsor of the workshop “Eukaryotic Protein Expression for Pharmaceutical Research” and will feature the MaxCyte STX in stand G16.

“The ability and versatility of the MaxCyte STX to transfect any cell quickly and reproducibly with any combination of molecules from the bench to HTS scale is proving to be a valuable and cost-effective tool for pharmaceutical companies,” says Douglas Doerfler, President and CEO of MaxCyte. “We are delighted to have the opportunity to demonstrate how to accelerate assay development and drug candidate screening using the MaxCyte STX and to participate in the MipTec 2010 Conference.”

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed the MaxCyte® STX™ Scalable Transfection System for the rapid development and consistent production of (co)transfected primary cells, stem cells, and cell lines for cell-based screening assays for ion channels, GPCRs, and other targets, with comparable results and Seamless Scalability™ from the bench to HTS scale.

For more information, <http://www.maxcyte.com/cell-based-screening.shtml>.

###